2019-06-20

Decisions from Annual General Meeting of Lipidor AB, 20 June 2019

(Stockholm 20 June, 2019) On 20 June2019, the Annual General Meeting (”AGM”) of Lipidor AB (publ) was held in Stockholm. Read below for a summary of the decisions made. 

Reporting



The AGM approved the balance sheet and profit and loss statement for the financial year 2018.



Dividend



In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2018. 



Discharge from liability



The board of directors and the CEO were discharged from liability for the financial year 2018. 



Board of directors



Ola Flink, Gabriel Haering, Per Nilsson and Fredrik Sjövall were re-elected as board members and Gunilla Lundmark was elected as new board member. It was noted that Magnus Hedman had declined to be re-elected. Ola Flink was re-elected as Chairman of the board of directors.  



It was resolved that remuneration to the board of directors will amount to a maximum of SEK 400,000 in total, of which a maximum of SEK 200,000 for the Chairman of the board and a maximum of SEK 100,000 to every other independent board member.  



PwC AB was re-elected as auditor, with the authorised public accountant Magnus Lagerberg as principle auditor. It was resolved that remuneration to the auditor will be according to approved invoicing. 



Authorisation for the board of directors to resolve on new issues of shares, share warrants or convertibles



In accordance with the board's proposal, the board of directors was authorised to decide,on one or several occasions during the time up to the next AGM, with or without deviation from the shareholders’ preferential right, on issue of new shares, warrants or convertibles. The authorization shall also include right to decide on issue of shares with provision stating that payment may be made against cash, in kind or through set-off. The authorization shall be limited whereby the Board of Directors may not resolve to issue shares, or in case of issue of convertibles or warrants that involve conversion into shares or subscription following exercise of warrants, corresponding to more than 10,000,000 shares, corresponding to 34 % of the total number of shares in the Company at the time of the exercise of the authorization. 



 

For more information, please contact:



Ola Holmlund, CEO, Lipidor AB



Phone: +46 72 5070369



E-mail: ola.holmlund@lipidor.se

 



About Lipidor



Lipidor AB is a Swedish, Stockholm based company developing topical products offering unique lipid based formulation opportunities across Pharma, Consumer Healthcare and Animal Care. 



The company was established in 2009. Research and development is conducted at Stockholm University and Karolinska Institutet Science Park in Stockholm.



www.lipidor.se